drugset / Trial / NCT06272409

Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.

NCT06272409

Phase 3 Not yet recruiting 318 enrolled EMS
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of DEP114 in the treatment of Moderate to Severe Persistent Allergic Rhinitis in children aged between 6 and 11 years.

Timeline

Start
2025-02-15
Primary completion
2025-03-15
Completion
2027-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject DEP114 Unknown Oral
Comparator Desloratadine Small molecule 0.5 mg/ml Oral

Indications